Key terms
About HLVX
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest HLVX news
Mar 25
10:10pm ET
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
Mar 21
6:16am ET
HilleVax, Inc’s HIL-214 Vaccine Candidate Promises Broad Protection Against Norovirus, Justifying Buy Rating
Mar 20
4:59pm ET
HilleVax files $500M mixed securities shelf
Mar 20
4:26pm ET
HilleVax reports Q4 EPS (78c), consensus (83c)
Jan 19
3:05am ET
HilleVax, Inc. Announces Executive Team Restructuring
Jan 18
7:08am ET
HilleVax appoints McLoughlin as Chief Operating Officer
Jan 08
7:31am ET
HilleVax, Kangh announce exclusive license agreement for HIL-216
No recent press releases are available for HLVX
HLVX Financials
Key terms
Ad Feedback
HLVX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
HLVX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
